Top Performer of the day: Synergy Pharmaceuticals, Inc. (SGYP)


Synergy Pharmaceuticals, Inc. (SGYP) belonging to the Medical sector has declined -3.43% and closed its last trading session at $5.07.

The company reported its EPS on 03/02/2017. Currently, the stock has a 1 Year Price Target of $11.5.

The consensus recommendation, according to Zacks Investment research, is 1. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.

The Stock had a 1 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1 and 1 respectively.

Synergy Pharmaceuticals, Inc. on 03/02/2017 reported its EPS as $-0.31 with the analysts projecting the EPS of the stock as $-0.2. The company beat the analyst EPS Estimate with the difference of $-0.11. This shows a surprise factor of -55%.

Many analysts have provided their estimated foresights on Synergy Pharmaceuticals, Inc. Earnings, with 2 analysts believing the company would generate an Average Estimate of $-0.18.

Whereas they predicted High and Low Earnings Estimate as $-0.16 and $-0.2 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.51.

Analysts are also projecting an Average Revenue Estimate for Synergy Pharmaceuticals, Inc. as $50 Million in the Current Quarter. This estimate is provided by 2 analysts.

For the Current Quarter, the growth estimate for Synergy Pharmaceuticals, Inc. is 64.7%, while for the Next Quarter the stock growth estimate is 34.8%.

The Company got Initiated by Oppenheimer on 5-Jan-17 to Outperform.

Insider Trades for Synergy Pharmaceuticals, Inc. show that the latest trade was made on 3 Nov 2016 where PAULSON & CO INC, the Beneficial Owner of More than 10% Class completed a transaction type “Sell” in which 140000 shares were traded at a price of $4.24.

2 Insider Sales transactions were made totaling 23754 shares traded.

6 analysts projected Price Targets for Synergy Pharmaceuticals, Inc.. The analysts believe that the company stock price could grow as high as $18. The Low Price target projection by analysts is $6.5 and the Mean Price Target is $11.5.

Synergy Pharmaceuticals, Inc. (SGYP) has the market capitalization of $1.13 Billion. The company rocked its 52-Week High of $7.15 on Jan 31, 2017 and touched its 52-Week Low of $2.5 on Mar 23, 2016.

The stock has Return on Assets (ROA) of -182 percent. Return on Equity (ROE) stands at -876.7% and Return on Investment (ROI) of 0 percent.

The stock is currently showing YTD performance of -16.75 Percent. The company has Beta Value of 1.56 and ATR value of 0.26. The Weekly and Monthly Volatility stands at 4.14% and 5.26%.